OrthoPediatrics (KIDS) Q3 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- -$0.23
- Estimate
- -$0.21
- Surprise
- -7.0%
- Score today
- 5.5/10
Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.
How the report landed
OrthoPediatrics (KIDS) reported a wider loss than forecast — adjusted EPS of -$0.23 against the -$0.21 estimate (a 7.0% shortfall).
Coverage in the report window
- Lake Street Maintains Buy on OrthoPediatrics, Raises Price Target to $38 — benzinga, 2026-10-28
- Canaccord Genuity Maintains Buy on OrthoPediatrics, Raises Price Target to $30 — benzinga, 2026-10-28
- Truist Securities Maintains Hold on OrthoPediatrics, Raises Price Target to $28 — benzinga, 2026-10-28
Where TrendMatrix's rating stands now
TrendMatrix currently rates KIDS Sell at 5.5/10; no pre/post engine snapshot brackets this report.
3 of the last 4 quarters beat the estimate; this quarter's -7.0% surprise compares with a +3.7% four-quarter average. Next scheduled report: 2027-02-25.
What argues against it
- Target reached (-14.6% upside)
- Quality below floor (4.0 < 4.0)
- Negative risk/reward — downside exceeds upside
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $30.80
- Stop
- $28.64
Risk check: RSI 86 — a level conventionally read as overbought; gains at these levels often lean on momentum; trading volume is running 5.5× its average — elevated turnover around the report window.
Model outputs from TrendMatrix’s engine as of 2026-10-29 — shown for context, not personalized investment advice.
KIDS at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Medical Devices
- Market cap
- $804.2M
- P/E (fwd)
- -40.8
- 52-week range
- $14.42–$31.51
- Off 52-week high
- 2.3%
- RSI (14)
- 86
- Volume vs avg
- 5.48×
- Score today
- 5.5/10